Fortis Healthcare today said it has reported a consolidated net loss of Rs 60.42 crore for the quarter ended June 30, 2012 due to higher interest costs and adverse currency fluctuations.
The company had posted a consolidated net profit of Rs 16.01 crore in the corresponding period last fiscal, Fortis Healthcare said in a statement.
Consolidated total income of the company, however, rose to Rs 1,409.29 crore for the quarter under consideration from Rs 484.82 crore for the same period a year ago.
Commenting on the results, Fortis Healthcare Group CEO Vishal Bali said: "Our strong operating performance both in India and across International assets reflects the strength of our businesses and the growth potential across all our markets".
The India business of the company contributed 47.5% to consolidated revenues for the April-June quarter.
For the first quarter this fiscal, revenues from India hospital business stood at Rs 532 crore while the diagnostics business posted revenues of Rs 137 crore, Fortis Healthcare said.
The company also concluded its PE investment transaction in Super Religare Laboratories (SRL) with NYLIM Jacob Ballas India Fund III LLC, Mauritius and International Finance Corporation investing Rs 250 crore and Rs 120 crore, respectively in the form of compulsorily convertible preference shares (CCPS), it added.
The proceeds received at the end of the quarter have been primarily used for reducing the company's debt position.
International business of the company contributed 52.5% to the consolidated revenues and stood at Rs 741 crore for the quarter, it added.
During April-June period, the company commissioned Fortis Colorectal Hospital (FCH) in Singapore. The hospital specialises in the treatment of colorectal diseases, the company said.
Fortis Healthcare currently has a network of 75 hospitals with over 12,000 beds, over 600 primary care centres, 191 day care speciality centres, over 230 diagnostic centres and a talent pool of over 23,000 people.
Shares of Fortis Healthcare today closed at Rs 101.15 apiece on BSE, up 1.81% from their previous close.